MindMaze formerly Relief Therapeutics

What MindMaze formerly Relief Therapeutics does

MindMaze Therapeutics is a dual-platform digital neurotherapeutics and biopharmaceutical company formed in December 2025 through the business combination of Relief Therapeutics and NeuroX Group SA, trading on SIX Swiss Exchange (MMTX) and OTCQB (RLFTF). The digital neurotherapeutics portfolio comprises FDA-cleared and CE-marked products — MindMotion GO, MindPod, Izar, Physilog, ToapRun, and the MindMotion Companion home-engagement layer — designed to deliver gamified, AI-personalized motor, cognitive, and gait rehabilitation for stroke, Parkinson's, and broader neurological conditions. The platform runs a hybrid deterministic-plus-adaptive AI architecture that ingests approximately one million behavioral data points per month across multimodal sensor streams, supported by roughly 120 patent applications covering hardware, algorithms, and clinical protocols.

The biopharmaceutical arm develops treatments for rare and serious diseases, with disclosed pipeline assets including RLF-TD011, RLF-OD032, and RLF-100. MindMaze commercializes through hospital and rehabilitation-clinic channels, with 100+ hospital deployments and 250+ clinic installations worldwide spanning anchor accounts such as Mount Sinai, Vibra Healthcare, Johns Hopkins, Shirley Ryan AbilityLab, University College London, and University of Auckland. Revenue mechanics combine hardware/software sales, recurring clinical service fees, and — most recently — CPT Category III–coded home-based digital neurotherapy sessions, a billing pathway intended to enable sustained adoption outside acute-care settings. The company was founded in 2012 by Tej Tadi in Lausanne, Switzerland, with a US headquarters opened at The Pearl in Charlotte, North Carolina in July 2026, and approximately 101-250 employees.

Name

MindMaze formerly Relief Therapeutics

Legal name

MindMaze Therapeutics SA

Website

https://mindmazetherapeutics.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

MindMaze Therapeutics is a dual-platform digital neurotherapeutics and rare-disease biopharmaceutical company, commercializing FDA-cleared, AI-driven rehabilitation products for stroke and Parkinson's patients across 100+ hospitals and 250+ clinics globally.

Ownership category

akta.pro rank

Product category

Digital Neurotherapeutics and Rare Disease Biopharmaceuticals

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Digital neurotherapeutics
• Neurorehabilitation platform
• Digital motion analytics
• Rare disease therapeutics
• Behavioral biotechnology

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Digital Neurotherapeutics Platform: Revenue from FDA-cleared and CE-marked digital neurotherapeutic solutions deployed in hospitals, rehabilitation facilities, and patient homes. The company has secured US CPT Category III reimbursement codes for home-based therapy and is pursuing European reimbursement through clinical evidence generation.
2. Biopharmaceutical Portfolio: Revenue from Relief Therapeutics' drug portfolio focused on rare dermatological, metabolic, and respiratory diseases. Includes marketed products like PKU GOLIKE, diclofenac formulations, and SETOFILM/ONDISSOLVE marketed through licensing partnerships.
3. Clinical Research Services: Revenue from partnerships with pharmaceutical companies using MindMaze's proprietary technology across multiple clinical trials. The company generates evidence through sponsored clinical studies.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

MindMaze Therapeutics sells an FDA-cleared and CE-marked AI-powered digital neurotherapeutics platform for neurological recovery, including MindPod, MindMotion GO, Izar, Physilog, ToapRun, and MindMotion Companion, sold to hospitals, rehabilitation facilities, and healthcare providers. The company also markets and develops a portfolio of biopharmaceutical products for rare dermatological, metabolic, and respiratory diseases inherited from Relief Therapeutics.

Product overview

MindMaze Therapeutics operates as a dual-engine platform combining digital neurotherapeutics with biopharmaceutical products. The core MindMaze neurotherapeutics platform provides precision motor and cognitive assessments and treatments through an integrated ecosystem of products: MindMotion GO (game-based neurorehabilitation for clinical and home use), MindPod (immersive neuro-animation platform), Izar (smart hand peripheral), Physilog (motion analytics), ToapRun (Parkinson's gait therapy), and MindMotion Companion (monitoring and telehealth platform). The platform is enhanced by R&D initiatives including CogniChip (digital twin), MindDrive (motorsport neurotechnology), and MindSense (biometric decoding). Complementing the digital business, Relief Therapeutics contributes a portfolio of rare disease drugs including RLF-TD011 (epidermolysis bullosa), RLF-OD032 (phenylketonuria), RLF-100 (pulmonary indications), and commercialized products PKU GOLIKE, ACER-001, diclofenac formulations, and SETOFILM/ONDISSOLVE. The company holds FDA, CE/MDR, and EU MDR regulatory registrations with CPT Category III reimbursement for home-based therapy in the US.

Differentiator

Problem solved

Functional benefit

Brands

• MindMotion GO: First-of-its-kind neurorehabilitation platform using game-based digital therapies for patient training within inpatient and outpatient clinics as well as at home
• MindPod
• Izar
• Physilog
• ToapRun
• MindMotion Companion
• CogniChip
• MindDrive
• MindSense

Products and services

• MindPod Immersive neuro-animation platform providing high-intensity, high-dose training of motor and cognitive function through an animated gaming environment with a dolphin character, using motion-sensors and cameras to track patient movements in real time for brain recovery and learning.
• MindMotion GO First-of-its-kind neurorehabilitation system using game-based digital therapies for in-clinic, outpatient, and home settings, enabling high-dose, high-intensity training across the continuum of care for stroke and neurological patients.
• Izar First-in-kind FDA-listed and CE-marked hyper-sensitive smart controller for patients with hand motor function impairment; detects sub-newton finger and hand forces, enabling treatment in most impaired populations and training dexterity and strength through proprietary gaming content.
• Physilog 3D motion analytics solution that captures, measures, and analyzes digital biomarkers for patient-centric Digital Motion Assessments.
• ToapRun Game-based therapy for Parkinson's gait and balance developed in partnership with Institut du Cerveau in Paris.
• MindMotion Companion Patient monitoring and telehealth platform enabling therapists to track patient progress, schedule videoconferences (via Zoom), and manage home-based therapy programs for neurorehabilitation patients.
• CogniChip End-goal cognitive platform designed to simultaneously process and coordinate all sensory and physical inputs the brain experiences, combining elements to create a virtual self with applications spanning healthcare, transport, aviation, gaming, communications, and sports.
• MindDrive Next-generation safety and performance platform for motorsport monitoring driver brain activity and delivering targeted feedback to enhance focus, performance, and overall safety.
• MindSense Biometric data technology that decodes mental states such as focus, cognitive load, fatigue, and preference to provide athletes and sports organizations with neurocognitive intelligence.
• RLF-TD011 Differentiated hypotonic, acid-oxidizing solution formulated with hypochlorous acid for treatment of epidermolysis bullosa, granted Orphan Drug Designation by FDA.
• RLF-OD032 Innovative, highly concentrated liquid formulation of sapropterin dihydrochloride for oral administration for treatment of phenylketonuria, pursuing 505(b)(2) NDA pathway.
• RLF-100 (Aviptadil acetate) Proprietary, patent-protected Aviptadil formulations for intravenous and inhaled administration targeting acute respiratory distress syndromes and chronic lung diseases.
• ACER-001 Proprietary taste-masked formulation of sodium phenylbutyrate powder for urea cycle disorders, marketed as OLPRUVA in US by Zevra Therapeutics, with Relief holding exclusive rights for Europe.
• PKU GOLIKE First prolonged-release medical food for dietary management of phenylketonuria with special coating enabling more physiological absorption, marketed in US by Eton Pharmaceuticals.
• Diclofenac Formulations Portfolio of diclofenac formulations for multiple pain and inflammatory conditions including migraine, arthritis, and localized pain, out-licensed to third parties under brands including CAMBIA, Voltfast, and Diclo-ratiopharm.
• SETOFILM/ONDISSOLVE Orodispersible film formulation of ondansetron for prevention and treatment of nausea and vomiting, marketed as SETOFILM by Norgine in Europe and ONDISSOLVE by Takeda in Canada.

Quantifiable outcome

• 60% increase in additional therapy per day for stroke patients using MindMaze technology vs standard of care
• +3 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability10 records

Feature10 records

Partnerships

13 partnerships are on record, tiered minor and core.

• University of PittsburghminorStrategic or Co-development Partner · 9 July 2026MindMaze announced its precision neurotherapeutics technology is being used in a University of Pittsburgh study evaluating combination approach to post-stroke arm recovery. Study pairs cervical epidural spinal cord stimulation with intensive neurotherapy, testing whether combining stimulation with high-volume, intent-driven practice can produce lasting recovery gains beyond stimulation alone.
• SwissNeuroRehab ConsortiumcoreStrategic or Co-development Partner · 1 July 2026CHF 11.2 million Innosuisse-backed SwissNeuroRehab study evaluating 300 minutes of active training weekly across inpatient, outpatient, and home phases over 15-month follow-up period. First patients enrolled at six Swiss centers. Strategic effort to generate clinical and health-economic evidence for at-home reimbursement in European healthcare systems.
• Hospices Civils de LyoncoreStrategic or Co-development Partner · 1 July 2026REACT-AVC study at France's Hospices Civils de Lyon focused on early outpatient and home-based stroke rehabilitation, coordinated with SwissNeuroRehab study. Strategic effort for European at-home reimbursement evidence generation.
• Connect Labs by WexfordminorImplementation/ SI/ Consulting Partner · 28 May 2026MindMaze established US headquarters at Connect Labs by Wexford at Charlotte's The Pearl Innovation District, a partnership between Atrium Health and Wexford Science & Technology. Space includes Patient Experience Center with complete MindPod installation. The Pearl includes other tenants like IRCAD North America, Siemens Healthineers, and Tract Bio.
• NeuroX Group SAcoreStrategic or Co-development Partner · 2 October 2025Business combination forming MindMaze Therapeutics combining NeuroX Group SA (successor of MindMaze with digital neurotherapeutics) and Relief Therapeutics (biopharmaceutical portfolio). Transaction valued NeuroX at 1 billion Swiss francs ($1.1 billion) and Relief at 100 million francs. Listed on SIX Swiss Exchange under ticker MMTX.
• Vibra HealthcarecoreStrategic or Co-development Partner · 7 December 2022MindMaze partnered with Vibra Healthcare, a leader in post-acute hospital patient care operating 90+ specialty hospitals in 19 states, to deploy MindMaze's digital health technology platform (MindPod and MindMotion GO) in-clinic and at-home. The partnership facilitates large-scale rollout across inpatient, post-acute, community sub-acute and home-based care environments. Results from two-year multi-site quality improvement program with 210 patients across five Vibra facilities showed 60% increase in therapy per day and significantly enhanced functional recovery.
• Mount Sinai Health SystemcoreStrategic or Co-development Partner · 8 November 2022MindMaze partnered with Mount Sinai Health System, one of the largest academic medical systems in the New York metro area, to pioneer a digital neurotherapeutic program accelerating patient access to novel digital interventions. The program delivers superior outcomes in motor and cognitive function through high-dose, high-intensity training including home-based digital neuro-care, assessment, and monitoring for acute and long-term recovery after stroke and concussion. Peer-reviewed Arbuckle et al. 2025 publication reports improved clinical outcomes and cost savings from home-based stroke rehabilitation.
• Alfa Romeo F1 Team ORLENminorStrategic or Co-development Partner · 11 July 2022MindMaze entered strategic partnership with Alfa Romeo F1 Team ORLEN to advance brain health, safety, and performance technologies. MindDrive platform monitors driver brain activity to enhance focus, performance, and safety. Partnership includes brand sponsorship on drivers' helmets and research at Miami Grand Prix. MindMaze also has research partnerships with Andretti Autosport Indycar team and previous partnerships with McLaren and Haas F1 teams.
• The University of AucklandcoreStrategic or Co-development Partner · 21 September 2021MindMaze partnered with The University of Auckland on Phase 2 ESPRESSo trial evaluating MindPod for early stroke intervention within two weeks of stroke. The trial assesses high-intensity, high-dose exploratory arm and hand movements for upper limb motor capacity recovery. University provides predictive tool for recovery outcomes validation in US.
• Johns Hopkins UniversitycoreStrategic or Co-development Partner · 1 January 2020MindMotion GO adopted by Johns Hopkins, one of the foremost academic medical centers in the US. Dr. John Krakauer, Professor of Neurology and Neuroscience at Johns Hopkins, serves as Chief Medical and Scientific Advisor to MindMaze. MindPod technology developed with Dr. Omar Ahmad and Dr. Krakauer from Kata studio at Johns Hopkins.
• Genious HealthcareminorImplementation/ SI/ Consulting Partner · 1 January 2019Acquisition of Genious Healthcare added ToapRun to MindMaze's portfolio - a game-based therapy for Parkinson's gait and balance developed with Institut du Cerveau in Paris.
• MSquare HealthcareminorImplementation/ SI/ Consulting Partner · 1 January 2018Acquisition of MSquare Healthcare secured foundation of MindPod therapy system for MindMaze platform.
• CHUV (Centre Hospitalier Universitaire Vaudois)minorStrategic or Co-development Partner · 1 January 2013Clinical collaboration began with CHUV in Lausanne to test hospital neurorehabilitation platform for stroke. MindMotion PRO entered pre-clinical testing at CHUV. EPFL partnership formed foundation for MindMaze's origins and patent filing for Upper Limb Rehabilitation System.

Scale indicators9 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Hinge Health, Inc. Hinge Health is a leading digital musculoskeletal therapy platform with broader scope than MindMaze (covers MSK rather than neurological conditions specifically), but operates with a similar enterprise sales motion to employers/payors and applies digital therapeutic + coach delivery model.
• Medtronic plc: Medtronic is a global medtech incumbent with extensive neuroscience and rehabilitation portfolios, including neurostimulation and brain therapies — a broad incumbent that competes for the same hospital budgets and clinical decision-makers as MindMaze's neurotherapeutic platform.
• Stryker Corporation: Stryker's neurotechnology and surgical solutions divisions overlap with MindMaze's clinical customer base and broader rehabilitation/wearable strategy; Stefanie Scheurer (MindMaze's VP Sales Northern Europe) joined from Stryker, reflecting the talent and competitive overlap.
• Akili Interactive Labs, Inc. Akili is a digital therapeutics company with FDA-cleared products for cognitive conditions (ADHD, cognitive dysfunction) — a broader portfolio peer that pioneered the digital therapeutics regulatory and reimbursement pathway relevant to MindMaze's CPT Category III codes.

Direct peers

• Penumbra, Inc. Penumbra's REAL Immersive System is a VR-based digital neurorehabilitation platform targeting stroke and other neurological recovery — directly overlapping with MindMaze's MindPod and MindMotion GO in both indication and care-setting (clinical + home).
• Constant Therapy Health: Constant Therapy provides digital cognitive and speech therapy software for stroke and TBI recovery — a direct peer in the digital neurotherapeutics category serving the same clinician/patient base with software-based therapy delivery.
• Bionik Laboratories Corp. Bionik Laboratories develops robotic and digital neurorehabilitation technologies for stroke and other neurological conditions — directly comparable in product category and target customer (rehabilitation hospitals and clinics).
• Zevra Therapeutics, Inc. Zevra Therapeutics holds the US marketing rights for ACER-001 (sodium phenylbutyrate/Olpruva), which is the same compound for which MindMaze (via Relief Therapeutics) holds European rights — making Zevra a direct commercial peer in the rare disease biopharma side of the business.
• Saebo, Inc. Saebo manufactures neurorehabilitation products for stroke and upper-limb impairment including functional electrical stimulation devices, directly comparable to MindMaze's Izar smart peripheral for hand motor function and the broader neurorehab product suite.

Emerging players

• Neuro Rehab VR: Neuro Rehab VR develops VR-based neurorehabilitation experiences for clinical settings, targeting overlapping indications (stroke, TBI) with a similar gamified digital therapeutic approach but at an earlier commercial stage than MindMaze.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/relief-therapeutics-holding-sa
• YouTubeyoutube.com/channel/UCzXQ9XLjvhwQkI6zNbMhQQg
• Xx.com/MindMazeTx
• Facebookfacebook.com/MindMazeTx

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries5 records

Funding overview

Funding rounds7 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MindMaze formerly Relief Therapeutics